share_log

Kaisa Health Group Holdings' (HKG:876) Profits May Not Reveal Underlying Issues

Kaisa Health Group Holdings' (HKG:876) Profits May Not Reveal Underlying Issues

佳兆業健康集團控股公司 (HKG: 876) 的利潤可能不會顯示潛在問題
Simply Wall St ·  2023/10/02 20:44

Kaisa Health Group Holdings Limited (HKG:876) just released a solid earnings report, and the stock displayed some strength. While the profit numbers were good, our analysis has found some concerning factors that shareholders should be aware of.

佳兆業健康集團控股有限公司(HKG:876)剛剛發佈了穩健的盈利報告,該股顯示出一定的強勢。雖然利潤數位不錯,但我們的分析發現了一些值得股東關注的因素。

Check out our latest analysis for Kaisa Health Group Holdings

查看我們對佳兆業健康集團控股的最新分析

earnings-and-revenue-history
SEHK:876 Earnings and Revenue History October 3rd 2023
聯交所:876盈利及收入歷史2023年10月3日

The Impact Of Unusual Items On Profit

異常專案對利潤的影響

To properly understand Kaisa Health Group Holdings' profit results, we need to consider the HK$38m gain attributed to unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. We can see that Kaisa Health Group Holdings' positive unusual items were quite significant relative to its profit in the year to June 2023. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

要正確理解佳兆業健康集團控股的盈利業績,我們需要考慮歸因於不尋常專案的3800萬港元收益。我們不能否認,更高的利潤通常會讓我們保持樂觀,但如果利潤是可持續的,我們更願意這樣做。當我們分析了數千家上市公司的數據時,我們發現,在給定的一年裡,不尋常的專案往往會帶來提振第二年又重複了一遍。考慮到這個名字,這並不令人驚訝。我們可以看到,佳兆業健康集團控股的積極異常專案與其截至2023年6月的年度利潤相比相當重要。在其他條件不變的情況下,這可能會使法定利潤成為衡量潛在盈利能力的糟糕指標。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Kaisa Health Group Holdings.

注:我們總是建議投資者檢查資產負債表的實力。點擊此處查看我們對佳兆業健康集團控股的資產負債表分析。

Our Take On Kaisa Health Group Holdings' Profit Performance

我們對佳兆業健康集團控股公司盈利表現的看法

As we discussed above, we think the significant positive unusual item makes Kaisa Health Group Holdings' earnings a poor guide to its underlying profitability. As a result, we think it may well be the case that Kaisa Health Group Holdings' underlying earnings power is lower than its statutory profit. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. If you want to do dive deeper into Kaisa Health Group Holdings, you'd also look into what risks it is currently facing. To that end, you should learn about the 3 warning signs we've spotted with Kaisa Health Group Holdings (including 1 which is concerning).

正如我們上面討論的,我們認為這一重要的積極的不尋常專案使佳兆業健康集團控股公司的收益成為衡量其潛在盈利能力的糟糕指南。因此,我們認為很可能是佳兆業健康集團控股的基礎盈利能力低於其法定利潤。好的一面是,該公司在去年虧損後,表現出了足夠的改善,今年實現了盈利。本文的目的是評估我們可以在多大程度上依賴法定收益來反映公司的潛力,但還有很多東西需要考慮。如果你真的想更深入地研究佳兆業健康集團控股公司,你還應該調查它目前面臨的風險。為此,您應該瞭解3個警示標誌我們已經發現了佳兆業健康集團控股公司(包括1家與之相關的公司)。

Today we've zoomed in on a single data point to better understand the nature of Kaisa Health Group Holdings' profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

今天,我們放大了一個數據點,以更好地瞭解佳兆業健康集團控股公司的利潤性質。但還有很多其他方式可以讓你瞭解一家公司的看法。一些人認為,高股本回報率是高質量企業的良好標誌。所以你可能想看看這個免費擁有高股本回報率的公司的集合,或內部人士正在購買的這份股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫.或者,也可以給編輯組發電子郵件,地址是暗示Wallst.com。
本文由Simply Wall St.撰寫,具有概括性.我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議.它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況.我們的目標是為您帶來由基本面數據驅動的長期重點分析.請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內.Simply Wall St.對上述任何一隻股票都沒有持倉.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論